

































































69. European Medicines Agency. COVID-19 Vaccine AstraZeneca: Product Information as approved by the CHMP on 29 January 2021, pending endorsement by the European Commission. 29 January 2021. Available from: [https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-astrazeneca-product-information-approved-chmp-29-january-2021-pending-endorsement\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-astrazeneca-product-information-approved-chmp-29-january-2021-pending-endorsement_en.pdf) (Accessed 26 April 2021).
70. Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *The Lancet* 2021;397:881-91.
71. Therapeutic Goods Administration (TGA). AusPAR: ChAdOx1-S - Australian Public Assessment Report. 2021. Available from: <https://www.tga.gov.au/auspar/auspar-chadox1-s> (Accessed 26 April 2021).
72. US National Institutes of Health. Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults. 2021. Available from: <https://clinicaltrials.gov/ct2/show/NCT04516746> (Accessed 26 April 2021).
73. AstraZeneca. AZD1222 US Phase III primary analysis confirms safety and efficacy. 25 March 2021. Available from: <https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy.html> (Accessed 29 April 2021).
74. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. *New England Journal of Medicine* 2021;384:1412-23.
75. Pritchard E, Matthews PC, Stoesser N, et al. Impact of vaccination on SARS-CoV-2 cases in the community: a population-based study using the UK's COVID-19 Infection Survey. 2021. Available from: <https://doi.org/10.1101/2021.04.22.21255913> (Accessed 29 April 2021).
76. Vasileiou E, Simpson CR, Robertson C, et al. Effectiveness of first Dose of COVID-19 vaccines against hospital admissions in Scotland: national prospective cohort study of 5.4 million people (preprint). *The Lancet*.
77. Harris RJ, Hall JA, Zaidi A, et al. Impact of vaccination on household transmission of SARS-COV-2 in England. 2021. Available from: <https://khub.net/documents/135939561/390853656/Impact+of+vaccination+on+household+transmission+of+SA+RS-COV-2+in+England.pdf/35bf4bb1-6ade-d3eb-a39e-9c9b25a8122a?t=1619601878136> (Accessed 10 May 2021).
78. Shah ASV, Gribben C, Bishop J, et al. Effect of vaccination on transmission of COVID-19: an observational study in healthcare workers and their households (preprint). *medRxiv* 2021.
79. Hyams C, Marlow R. Assessing the Effectiveness of BNT162b2 and ChAdOx1nCoV-19 COVID-19 Vaccination in Prevention of Hospitalisations in Elderly and Frail Adults: A Single Centre Test Negative Case-Control Study (Pre-print). *The Lancet* 2021.
80. Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. *The Lancet* 2020;396:1595-606.